Healthcare & Pharmaceuticals
GlaxoSmithKline provides research funding to doctors who write favorable opinions of depression drugs for children, despite evidence from clinical trials that the medication can cause anger and even suicide.
DaVita, a company that provides health care to patients with kidney problems, has agreed to pay $495 million to settle whistleblower complaints that the company conspired to overcharge the U.S. government. This is in addition to the $400 million that the company had to pay out last year.
Should lobbyists for biotech and food companies make the rules on what kind of food you have in your kitchen? Meet Mella Frewen, Suzy Renckens and Harry Kuiper: Three examples of how the industries take advantage of the European Food Safety Agency(EFSA) failure to properly regulate conflicts of interest.
In Bayer and the Global Compact, Phillipp Mimkes of the Coalition Against Bayer Dangers looks at Bayer's corporate history and why it may be at odds with the Compact, a partnership between the UN and big business. Here, Mimkes offers a few more reasons.
From golden rice to anti-viral tomatoes, is the biotech industry's third generation good medicine or good marketing? And, activists ask, what are the environmental consequences?
The Supreme Court ruled, in one of its most closely watched property rights cases in years, that fostering economic development is an appropriate use of the government's power of eminent domain.
Sun Pharma, India's biggest drug manufacturer, has been sent a warning letter about violations of manufacturing regulations at its Halol plant in Gujarat by the United States Food and Drug Administration (FDA). Indian companies supply as much as 40 percent of the drugs sold in the U.S.
Novartis, the Swiss pharmaceutical company, will appear before the Indian Supreme Court Wednesday to appeal against a patent rejection for a popular cancer drug. A decision in favor of the company could have a devastating impact on cheap supplies of many kinds of generic drugs for poor patients.
Appalled by the announcement of a collaboration between the National Cancer Institute (NCI) and General Motors (GM) on a breast cancer drug trial, activists today criticized the project as a profit-seeking move for the automobile corporation and the pharmaceutical companies involved.